Objective: Whereas Alzheimer disease (AD) is associated with inner retina thinning visualized by spectral-domain optical coherence tomography (SD-OCT), we sought to determine if the retina has a distinguishing biomarker for frontotemporal degeneration (FTD).
Results: Adjusting for age, sex, and race, patients with FTD had a thinner outer retina than controls (132 vs 142 mm, p 5 0.004). Patients with FTD also had a thinner outer nuclear layer (ONL) (88.5 vs 97.9 mm, p 5 0.003) and ellipsoid zone (EZ) (14.5 vs 15.1 mm, p 5 0.009) than controls, but had similar thicknesses for inner retinal layers. The outer retina thickness of patients correlated with MMSE (Spearman r 5 0.44, p 5 0.03). The highly predictive tauopathy subgroup (n 5 31 eyes) also had a thinner ONL (88.7 vs 97.4 mm, p 5 0.01) and EZ (14.4 vs 15.1 mm, p 5 0.01) than controls.
Conclusions: FTD is associated with outer retina thinning, and this thinning correlates with disease severity. Neurology ® 2017;89:1604-1611 GLOSSARY Ab 5 b-amyloid; AD 5 Alzheimer disease; ALS 5 amyotrophic lateral sclerosis; AUC 5 area under the curve; bvFTD 5 behavioral variant of frontotemporal degeneration; CBS 5 corticobasal syndrome; CI 5 confidence interval; ETDRS 5 Early Treatment of Diabetic Retinopathy Study; EZ 5 ellipsoid zone; FTD 5 frontotemporal degeneration; GCL 5 ganglion cell layer; INL 5 inner nuclear layer; IRA 5 Iowa Reference Algorithm; MMSE 5 Mini-Mental State Examination; ONL 5 outer nuclear layer; OPL 5 outer plexiform layer; PPA 5 primary progressive aphasia; PSP 5 progressive supranuclear palsy; RNFL 5 retinal nerve fiber layer; ROC 5 receiver operating characteristic; SD-OCT 5 spectral-domain optical coherence tomography; TDP-43 5 TAR DNA-binding protein 43.
Frontotemporal degeneration (FTD) is an underinvestigated neurodegenerative condition as common as Alzheimer disease (AD) in people under age 65.
1 FTD-associated neuropathology consists of 2 main proteinopathies: FTLD-tau, related to inclusions formed from the microtubule-associated protein tau; and FTLD-TDP, related to TAR DNA-binding protein 43 (TDP-43) containing inclusions. 1 Despite these neuropathologic links, FTD actually involves a heterogeneous group of syndromes with only modest correlation between clinical presentation and neuropathology. Furthermore, it can be difficult to clinically differentiate FTD from AD; up to 30% of patients clinically diagnosed with FTD later have a neuropathologic diagnosis of AD. [2] [3] [4] As therapies develop, biomarkers for the underlying pathology are critically important to assess clinical trial eligibility.
Spectral-domain optical coherence tomography (SD-OCT) enables high-resolution retinal imaging. 5 Ophthalmology clinics routinely use SD-OCT, and image measurements have high reproducibility. 6 SD-OCT has great biomarker potential as it is acquired in minutes, is inexpensive, is noninvasive, and has no known safety risks. SD-OCT studies have identified thinning of the inner retinal layers (retinal nerve fiber layer [RNFL] or ganglion cell layer [GCL]) in several neurodegenerative diseases including AD and amyotrophic lateral sclerosis (ALS), which is a TDP-43 proteinopathy related to FTD. [7] [8] [9] [10] Histopathology of optic nerves and retinas has corroborated the thinning associated with AD. 11 We have found progressive outer retina (photoreceptor layer) thinning by SD-OCT in mice caused by a mutation in Rp1, a microtubule-associated protein. 12 Thus we hypothesized that SD-OCT may show photoreceptor abnormalities in patients with FTD tauopathy since tau is also a microtubule-associated protein. In this study, we evaluated retinal layer thicknesses using SD-OCT in a large wellcharacterized cohort of patients with FTD compared to controls. Neurologists prospectively reviewed all patients in consensus conference and diagnosed FTD according to published clinical criteria. 1, 13 All patients with PSP met criteria for probable PSP.
14 Patients underwent a routine lumbar puncture and CSF was collected according to published standard operating procedures. 15, 16 CSF was analyzed for the total tau:b-amyloid (Ab) 1-42 ratio (Luminex; Austin, TX), an autopsy validated marker for AD. 2, 15, 16 Within 12 months of enrollment, patients underwent a Mini-Mental State Examination (MMSE) by neurologists masked to SD-OCT data.
Since autopsy became available for only 1 patient, we used a combination of previously validated CSF, genetic, and clinical data to define subgroups (tauopathy, TDP-43, and unknown pathology) of highly predictive pathologic subtypes. First, patients with a total tau:Ab ratio .0.34 were considered to have presumed AD and excluded from analyses. 2, 15, 16 Next, patients were genotyped according to risk of hereditary disease for pathogenic mutations in MAPT (OMIM:157140), progranulin (GRN) (OMIM:138945), C9orf72 (OMIM: 61426), and TARDBP p.I383V (OMIM: 605078; p.N39OS). 17 Finally, patients meeting criteria for clinical phenotypes of PSP, nonfluent PPA, and CBS were categorized as FTLD-tau, while those meeting criteria for the semantic variant of PPA were categorized as FTLD-TDP. 2, 14, [18] [19] [20] A group of 44 consecutive healthy controls without diabetes and intended for several different SD-OCT studies were prospectively enrolled (February 2015-April 2016) for retinal evaluation at the Scheie Eye Institute. Controls did not undergo cognitive testing but had no history of any neurodegenerative disease.
On the day of SD-OCT imaging, all patients and controls had a dilated eye examination to identify undiagnosed ophthalmic disease. Prior to analyses, we excluded participants (or eyes) with macular disease, diabetic retinopathy, hypertensive retinopathy, retinal vascular disease, glaucoma or optic nerve disease, high refractive error (66.00 D spherical equivalent), substantial ocular media opacity, intraocular surgery within 90 days of enrollment, poor image quality, or incomplete image scans (figure e-1 at Neurology.org). A few patient and control eyes had incidental peripheral retina examination findings not affecting the macula (table e-1). Two patients had a history of diabetes without retinopathy on examination.
Standard protocol approvals, registrations, and patient consents. This study was approved by the University of Pennsylvania institutional review board. All participants gave written informed consent (with caregivers when appropriate).
Imaging protocol and image analysis. All participants underwent SD-OCT imaging with the Heidelberg Spectralis (Heidelberg Engineering, Carlsbad, CA) with a standard macular volume scan protocol of 208 images, 25 high-resolution raster scans, and automated real time averaging of 25. An analyst masked to clinical information segmented individual retinal layers using the highly validated Iowa Reference Algorithm (IRA) (v3.6), and algorithm segmentation errors were manually corrected. [21] [22] [23] This algorithm segmented 11 optical interfaces (10 layers) and provided thickness readings for the 9 regions of the standard Early Treatment of Diabetic Retinopathy Study (ETDRS) grid centered at the fovea (figure e-2). We selected the central circle at the fovea (diameter 1 mm), the average of the central 5 regions (diameter 3 mm), and the average of all 9 regions (diameter 6 mm) for analyses. Total retina thickness was defined as the distance from the RNFL's inner boundary to the interdigitation zone's outer boundary. The outer retina thickness was defined as the distance from the outer nuclear layer's (ONL) inner boundary to the interdigitation zone's outer boundary. With this definition, the outer retina thickness focuses on the photoreceptor layers.
Statistical analyses. We used generalized linear models for comparing the thickness measures of retinal layers between patients and controls without and with adjustment of participant demographics (age, sex, and race). The intereye correlation of thickness for participants contributing 2 eyes was accounted for by using generalized estimating equations. 24, 25 Similar analyses were made for comparisons across subgroups of patients and each subgroup of patients vs controls using generalized linear models. The thickness calculated from these linear regression models (with and without adjustment for demographic characteristics) were summarized as mean and standard error. We calculated the area under the receiver operating characteristic (ROC) curve using logistic regression models to evaluate the ability of outer retinal thickness to discriminate patients diagnosed with FTD or tauopathy subgroup patients from controls. We evaluated the Spearman correlation of MMSE with outer retina thickness, ONL thickness, and ellipsoid zone (EZ) thickness. For the ROC analysis and correlation analysis, the average thickness of 2 eyes was used for participants contributing 2 eyes. Our study of 27 patients (46 eyes) and 44 controls (69 eyes) provides at least 80% power to detect an effect size of 0.55 or more for the comparison of thickness measures between patients and controls. All the statistical analyses were performed in SAS v9.4 (SAS Institute Inc., Cary, NC) and 2-sided p , 0.05 was considered statistically significant.
RESULTS Demographics. The reasons for prespecified exclusions are shown in figure e-1. This included 5 patients with presumed AD based on CSF biomarker analysis, 3 of whom were already excluded for poor image quality or confounding eye disease. After these exclusions, 27 patients (46 eyes) with a mean age of 66 years and 44 controls (69 eyes) with a mean age of 56 years were analyzed. The percent of male participants was similar (table 1) . There were no African American patients, but 21 of 44 (48%) controls were African American (p , 0.001).
Comparison of retinal layer thicknesses between patients with FTD and controls. The retinal thicknesses of patients was compared to that of controls for the average of the 5 central ETDRS subfields (table 2) . While total retinal thickness was not different between patients and controls, patients had a thicker outer plexiform layer (OPL) and thinner outer retinal layers (table 2) .
Next, retinal thicknesses were compared between patients and controls by adjusting for age, sex, and race. These results were similar and showed that patients as compared to controls had thinning of the outer retina, ONL, and EZ (table 2) . When the OPL and ONL were combined and analyzed as a single layer, patients still showed thinning compared to controls (117 vs 123 mm, p 5 0.02). We then excluded controls age #55 years, providing a group The ROC analysis for discriminating patients from controls found that the area under the curve (AUC) was 0.72 (95% confidence interval [CI] 0.60-0.84) for the outer retina thickness and 0.81 (95% CI 0.71-0.91) for outer retina thickness and age.
Presumed molecular pathology subgroup categorization and comparison. Of the 27 patients, all had CSF biomarker analysis except 6 who were unable to undergo CSF collection for logistical reasons. These 6 patients met clinical criteria for PSP, which is highly associated with a tauopathy neuropathologically. 14, 18, 19 Two patients had familial forms of FTD; one patient had a MAPT E10116 C.T mutation and one patient had a hexanucleotide expansion in C9orf72. No patient had a TARDBP mutation or GRN mutation. One patient who died during the study had a clinical diagnosis of PSP and a neuropathologic diagnosis of corticobasal degeneration, a 4-repeat tauopathy.
The tauopathy subgroup demographics are shown in table 1. This included the following: PSP (12), CBS (4), nonfluent PPA (2), and the patient with a pathogenic mutation in MAPT predictive of FTLD-tau. Adjusted analysis showed that the tauopathy subgroup as compared to controls had thinning of the outer retina, ONL, and EZ. All other subgroups, although too small for useful statistical analysis, showed ONL thinning that was not different from that in controls (table 3) .
The ROC analysis for discriminating the tauopathy subgroup and controls found that the AUC was 0.70 (95% CI 0.56-0.84) for outer retina thickness and 0.81 (95% CI 0.70-0.92) for outer retina thickness and age. Figure 1 demonstrates a tauopathy patient with ONL thinning compared to a control matched for age, sex, and race. This patient has a MAPT E10116 C.T mutation and was clinically diagnosed with bvFTD with features of the semantic variant of PPA.
Correlation of retinal layers with MMSE. Among patients with FTD, the outer retina and ONL thicknesses were positively correlated with MMSE (table 4) . The tauopathy subgroup did not have correlations with MMSE.
DISCUSSION While AD is associated with inner retina thinning, 7-9 our study revealed that FTD is associated with outer retina thinning. The FTD and tauopathy subgroup had thinning of both the ONL and EZ, and the outer retina thinning was driven by the ONL thinning. The ONL was, on average, about 10% thinner in patients with FTD compared to controls. FTD has distinct neuropathology compared to AD, and our finding that FTD is predominantly associated with photoreceptor layer (outer retina) thinning suggests that FTD also has retinal changes that appear to be distinct from AD. As potential mechanism-based therapeutics emerge, 26, 27 biomarkers predictive of pathology for FTD are critically important to more easily separate FTD from AD, and to separate FTLD-tau from FTLD-TDP. 1 While CSF biomarkers have utility, they require an invasive procedure, and CSF biomarkers differentiating FTLD-tau from FTLD-TDP require additional validation. 2 As a biomarker test, SD-OCT image acquisition has ideal features as it is quick, noninvasive, and low cost. The outer retina thickness had an AUC of 0.81 when combined with age, suggesting that an automated segmentation algorithm enables SD-OCT of the retina to have biomarker potential for FTD. Given ongoing biomarker studies in neuroimaging and CSF, it is possible that SD-OCT would best be used within a multiple biomarker model to predict underlying pathology.
2,28
The Henle nerve fiber layer usually is isoreflective with the ONL but is known to appear hyperreflective at some locations depending on the orientation of SD-OCT light in relation to the retina. 29 Therefore, some argue that it is difficult to accurately measure the ONL in relation to the OPL. Our ONL measurement includes the Henle layer, and there are several reasons to give confidence to our finding of ONL thinning in FTD. First, the IRA has previously shown the capability to accurately segment the OPL and ONL, 30 as also shown in figure 1 . Second, the analyst using the IRA was masked. Third, even when we combined the OPL and ONL thicknesses, we still 29 Point measurements of the ONL thickness were made using the caliper function of the Heidelberg Spectralis (Heidelberg Engineering, Carlsbad, CA) and labeled in white (mm).
found that patients had statistically significant thinning compared to controls. 29 Fourth, artifacts from the Henle layer would not affect EZ measurements. Our finding of EZ thinning in FTD further supports ONL thinning as 2 distinct and adjacent photoreceptor layers were abnormally thin.
Photoreceptors are sensitive to microtubuleassociated defects, as microtubules are critical to the structure and function of photoreceptor cilia. 31 We previously found that SD-OCT detects ONL thinning and EZ abnormalities in mice with an Rp1 mutation.
12 Therefore, we hypothesized that patients with FTD tauopathy may have similar findings, as Rp1 and tau are both microtubule-associated proteins within the proteome of photoreceptor cilia. 32 Our analysis of highly predictive molecular pathology found that the tauopathy subgroup, our largest group, also showed thinning of the ONL and EZ. Although immunohistochemistry studies of tau expression in the human retina have variable results, tau aggregates have been identified within photoreceptors. 33 Another report demonstrated phosphorylated tau predominantly in the inner nuclear layer (INL) of a patient with PSP, but did not include detailed analyses of retinal morphology. 34 Disease-specific p62 inclusions were also found within the INL of a patient with ALS with a C9orf72 mutation. 10 However, the same investigators found no inclusions and RNFL thinning in a different patient with ALS with no known mutation. 10 These varying studies alone do not exclude the possibility that a pathologic mechanism involving tau or TDP-43 could cause photoreceptor layer thinning. Additional immunohistochemistry studies with morphologic analyses and SD-OCT correlation in well-characterized patients with FTD are needed. Interestingly, our data also showed ONL thinning and EZ thinning in the probable TDP-43 pathology subgroup, but it was not significantly different from controls. The number of patients in this subgroup was small, making it difficult to draw any definite conclusions.
There is limited literature on the SD-OCT findings of FTD. Patients with clinically diagnosed PSP have been studied by 2 groups. Evaluating 15 patients with PSP, one group found thinning of both the GCL-inner plexiform layer and the ONL. 35 With 16 patients with PSP, the findings of another group included thinning of the INL and nonsignificant thinning of the ONL. 36 While both studies suggest that patients with PSP may have ONL thinning, inconsistencies between these studies and our study may stem from differences in segmentation methods or differences between the PSP groups and our presumed tauopathy subgroup. Recently, a different study found inner retina thinning in 17 patients with FTD. 37 It is difficult to directly compare our data with this study, which did not test for the CSF total tau:Ab biomarker to exclude AD and did not categorize patients by underlying molecular pathology. Their cohort could have a high proportion of patients with TDP-43 proteinopathy, and it is possible that these patients may have inner retina thinning compared to tauopathy patients. Indeed, inner retina thinning was reported in 12 patients with a progranulin mutation, a mutation associated with TDP-43 neuropathology. 38 Further work is needed to determine if patients with TDP-43 pathology have inner or outer retina thinning and how these patients compare to tauopathy patients.
Among our patients with FTD, we also found a positive correlation of outer retina thinning with MMSE. The nonsignificant correlation in the tauopathy subgroup may be related to sample size. Others have reported that inner retina thinning in patients with AD may also correlate with disease severity. 8 Our data suggest an additional utility of outer retina thickness measurements and the importance of larger, longitudinal studies to determine if outer retina thickness may estimate factors related to prognosis and survival.
The strengths of our study are twofold. First, we implemented a deep endophenotyping approach to patients with FTD based on highly predictive pathology. Our study carefully excluded confounding eye diseases with eye examinations and excluded patients with AD. Our notable number of excluded eyes and patients suggests the importance of this study design. We then uniquely grouped patients by presumed molecular pathology. FTD represents a heterogeneous group of clinical syndromes; this approach is important to reduce discrepancies between clinical diagnosis and molecular pathology. In the tauopathy subgroup, we demonstrated a direct relationship between outer retina thinning and a specific form of pathology. Second, we used the extensively validated IRA. Contrasting with other segmentation approaches, the IRA enables detailed outer retina segmentation, leading to our finding of EZ thinning in patients with FTD. Importantly, the IRA has demonstrated excellent capability of identifying inner retina thinning, but did not show inner retina thinning in our patients with FTD. 39 One weakness of our data is the different demographics of controls and patients. While all patients were recruited consecutively, differences reflect the different populations of FTD vs controls recruited during a routine eye examination. Indeed, FTD is considerably less common in African Americans. 40 To account for demographic differences, we adjusted for age, sex, and race. In addition, when we removed the African American participants from the control group or reached an age-matched control group by excluding those age #55 years, we still found that patients had significant outer retina thinning compared to controls. Another caveat of our data is the limited number of patients in the nontauopathy subgroups; this must be considered before generalizing our results to all patients with FTD.
Using the IRA and a deep endophenotyping approach to patients primarily composed of presumed tauopathy molecular pathology, our study revealed that FTD is predominantly associated with outer retina thinning, including thinning of the ONL and EZ. This contrasts with the inner retina thinning typically seen in AD. Furthermore, the outer retina thinning in FTD correlates with MMSE. Our study suggests that measurements of retinal thickness have the potential to serve as biomarkers for FTD and may relate to disease severity. Future work should focus on direct comparison of AD patients with FTD patients and comparison of the different subgroups of FTD using similar methods and longitudinal studies with autopsy confirmation.
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